Taylor, P., Keystone, E., Van der Heijde, D., Weinblatt, M., del Carmen Morales, L., Reyes Gonzaga, J., . . . Tanaka, Y. (2017). Baricitinib versus placebo or adalimumab in rheumatoid arthritis. Massachusetts Medical Society.
Citación estilo ChicagoTaylor, P., et al. Baricitinib Versus Placebo or Adalimumab in Rheumatoid Arthritis. Massachusetts Medical Society, 2017.
Cita MLATaylor, P., et al. Baricitinib Versus Placebo or Adalimumab in Rheumatoid Arthritis. Massachusetts Medical Society, 2017.
Warning: These citations may not always be 100% accurate.